Biotech · Private company · South San Francisco, CA, US
Unity Biotechnology, Inc.
SEC CIK 0001463361
Track this companyFree. Adds Unity Biotechnology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- AfliberceptPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- foselutoclaxPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- UBX0101Phase 2 · Osteoarthritis, KneeClinicalTrials.gov · fetched Nov 12, 2026
- UBX1325Phase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- UBX1325 injection 50 μLPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- UBX0101Phase 1 · Knee OsteoarthritisClinicalTrials.gov · fetched Nov 12, 2026
- UBX1325Phase 1 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)PHASE2 · COMPLETED · started Aug 23, 2023ClinicalTrials.gov NCT06011798 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)PHASE2 · COMPLETED · started Mar 2, 2022ClinicalTrials.gov NCT05275205 · fetched Nov 12, 2026
- Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)PHASE2 · COMPLETED · started Jun 25, 2021ClinicalTrials.gov NCT04857996 · fetched Nov 12, 2026
- Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular DegenerationPHASE1 · COMPLETED · started Oct 8, 2020ClinicalTrials.gov NCT04537884 · fetched Nov 12, 2026
- Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or PlaceboTERMINATED · started Apr 20, 2020ClinicalTrials.gov NCT04349956 · fetched Nov 12, 2026
- A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the KneePHASE1 · COMPLETED · started Jan 23, 2020ClinicalTrials.gov NCT04229225 · fetched Nov 12, 2026
- A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the KneePHASE2 · COMPLETED · started Oct 30, 2019ClinicalTrials.gov NCT04129944 · fetched Nov 12, 2026
- A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the KneePHASE1 · COMPLETED · started May 16, 2018ClinicalTrials.gov NCT03513016 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 26, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 19, 2025 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jul 24, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 22, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 30, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 20, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 22, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 22, 2025 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 11, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 4, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 24, 2025 · fetched Nov 12, 2026